The efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers: Results of a multi-centre, controlled, randomised, blinded, clinical trial

The Grafix Diabetic Foot Ulcer Study Group

Research output: Contribution to journalArticle

104 Scopus citations

Abstract

In a randomised, controlled study, we compared the efficacy of Grafix®, a human viable wound matrix (hVWM) (N = 50), to standard wound care (n = 47) to heal diabetic foot ulcers (DFUs). The primary endpoint was the proportion of patients with complete wound closure by 12 weeks. Secondary endpoints included the time to wound closure, adverse events and wound closure in the crossover phase. The proportion of patients who achieved complete wound closure was significantly higher in patients who received Grafix (62%) compared with controls (21%, P = 0·0001). The median time to healing was 42 days in Grafix patients compared with 69·5 days in controls (P = 0·019). There were fewer Grafix patients with adverse events (44% versus 66%, P = 0·031) and fewer Grafix patients with wound-related infections (18% versus 36·2%, P = 0·044). Among the study subjects that healed, ulcers remained closed in 82·1% of patients (23 of 28 patients) in the Grafix group versus 70% (7 of 10 patients) in the control group (P = 0·419). Treatment with Grafix significantly improved DFU healing compared with standard wound therapy. Importantly, Grafix also reduced DFU-related complications. The results of this well-controlled study showed that Grafix is a safe and more effective therapy for treating DFUs than standard wound therapy.

Original languageEnglish (US)
Pages (from-to)554-560
Number of pages7
JournalInternational Wound Journal
Volume11
Issue number5
DOIs
StatePublished - Oct 1 2014

Keywords

  • Diabetes
  • Infection
  • Stem cells
  • Ulcer

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint Dive into the research topics of 'The efficacy and safety of Grafix<sup>®</sup> for the treatment of chronic diabetic foot ulcers: Results of a multi-centre, controlled, randomised, blinded, clinical trial'. Together they form a unique fingerprint.

  • Cite this